OR WAIT null SECS
Rentschler Biopharma will establish its manufacturing capability for advanced therapy medicinal products at the CGT Catapult site in Stevenage, UK.
In a Feb. 11, 2021 press release, the Cell and Gene Therapy Catapult (CGT Catapult) and Rentschler Biopharma jointly announced that Rentschler Biopharma will establish its manufacturing capability for advanced therapy medicinal products (ATMPs) at the CGT Catapult site in Stevenage, United Kingdom.
As per the terms of the agreement, Rentschler Biopharma, a global contract and development organization (CDMO), will invest in the Stevenage site over the next five years to set up its manufacturing capabilities. These investments will be used to help meet the demand from UK and international researchers for suitable manufacturing capability and the site development is expected to strengthen the UK cell and gene therapy ecosystem.
“We are excited to take this next big step in our evolution and address the growing industry demand for ATMP manufacturing capacity and viral vector supply. With the largest industry cluster for cell and gene therapies outside the [United States], the UK is an ideal location for us to establish our Center of Excellence for cell and gene therapy,” said Dr. Frank Mathias, CEO of Rentschler Biopharma, in the press release. “We look forward to working with the CGT Catapult as we invest in this growing field. They are well established in this important market, enabling us to immediately tap into the organization’s network and utilise the UK’s strong expertise and supply chain in cell and gene therapy manufacturing.”
“We are very pleased that Rentschler Biopharma, a global CDMO, has chosen to build their ATMP capacity in the UK, bringing in their expertise and investment. This will build new capacity to benefit the international ATMP supply chain and meet growing academic and commercial demand across the industry,” added Matthew Durdy, CEO of the CGT Catapult, in the press release. “As more companies from around the globe come to the UK, it demonstrates and enhances the attractiveness of its cell and gene therapy ecosystem as a place to develop new technologies and capabilities.”
Source: Rentschler Biopharma